News zum Sektor Gesundheit aus Schweden

 

Synsam invites institutional investors, analysts, and financial media to a Capital Markets Day on September 24, 2025. The Capital Markets Day will be held in Stockholm at Västra Trädgårdsgatan 19. The event will begin at 1:00 PM and is expected to run until 4:30 PM, followed by a networking session with light refreshments. The purpose of the Capital Markets Day is to offer in-depth insights into Synsam Group's key strategic focus areas and provide an update on the Group's long-term strategy. Presentations will be given by senior executives from the Group, and participants will have the...

On 18 July 2025 at 08:00 am (CET), Attendo will present the interim report for April-June 2025. A webcast presentation will be held at 10:00 am (CET) on the same day. The presentation will be hosted by Attendo's CEO Martin Tivéus and CFO Mikael Malmgren. The presentation will be held in English.   You can follow the presentation on the following page: https://attendo.events.inderes.com/q2-report-2025 (https://urldefense.proofpoint.com/v2/url?u=https-3A__attendo.events.inderes.com_q2-2Dreport-2D2025&d=DwMFAw&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=D6HpmVI_wtO7MEX_...

Getinge will issue its Q2 Report 2025 on July 18, 2025, at 08.00 a.m. CEST, followed by a conference call at 10.00 a.m. CEST, hosted by Mattias Perjos, President & CEO, and Agneta Palmér, CFO. Fund managers, analysts and media are invited to participate in the conference call. To participate via teleconference, please register via this link (https://events.inderes.com/getinge/q2-report-2025/dial-in). After registration, you will be provided with telephone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference. During the...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company has signed an agreement with a top-tier global contract research organization (CRO) relating to the Phase IIb trial of CS1. The selection of a CRO is an important step in the clinical development for CS1 and marks a significant milestone toward the initiation of the Phase IIb trial. CS1 has the potential to become an effective disease-modifying treatment to enhance and extend life for...

This announcement is not an offer, whether directly or indirectly, in Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa or in any other jurisdiction where such offer pursuant to legislation, restrictions and/or regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled "Important...

The shareholders of Episurf Medical AB (publ), reg. no. 556767-0541 (“Episurf” or the “Company”), are hereby summoned to the Extraordinary General Meeting on 4 August 2025, at 14:00 (CEST) at the offices of Snellman Attorneys AB at Kungsträdgårdsgatan 20 in Stockholm, Sweden. Entry and registration opens at 13:30 (CEST). The Board of Directors has, pursuant to Chapter 7, Section 4 a of the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)) and the Company's Articles of Association, decided that the shareholders shall be able to exercise their voting rights by postal voting prior to the...

Nordic Growth Market NGM AB (“NGM”) has decided to delist Raytelligence AB (“the Company”)  from Nordic SME. Since July 26th, 2023, the Company has been traded under observation due to a significant change in its operations to such an extent that the Company appears to be a new enterprise and NGM decided to initiate an investigation corresponding to the listing process applicable to an entirely new company which applies for listing on Nordic SME. The purpose of the listing process is to ensure that the company, after the transaction, meets all listing requirements set forth in Rules for...

GOTHENBURG, Sweden, July 3, 2025 /PRNewswire/ -- Vitrolife AB (publ) will publish its Q2 2025 interim report on Thursday, 17 July 2025 at 08:00 am CEST. A conference call for investors, analysts and financial media will be held at 10:00 am CEST the same day. The presentation will be held......

NextCell Pharma AB's ("NextCell" or "the Company") has entered into a strategic collaboration with FUJIFILM Biosciences Inc. to bring together their core competences in mesenchymal stromal cells (MSCs) and raw materials for the life science sector. The aim of the collaboration is to provide researchers and developers in the cell therapy field with an integrated offering – standardised MSC products, optimised culture media, and cryopreservation solutions. As part of the rebranding of Fujifilm Irvine Scientific to FUJIFILM Biosciences, we are re-publishing the press release originally issued...

Lund, Sweden, 3 July 2025. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its interim report for January - June 2025 on 17 July 2025. Interested parties may join the Company's quarterly conference call on the same date at 14:00 CEST/8:00 AM ET. The event will be hosted by Renée Aguiar-Lucander, CEO, Evan Ballantyne, CFO, Hitto Kaufmann, CR&DO, and Maria Törnsén COO and President U.S. The call will include a review of the interim results and a business and pipeline update. It will be held in English.  Slides used in the presentation will be made available on the company...

STOCKHOLM, SWEDEN – July 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces an update from Organon on the development of the drug candidate OG-6219, acquired by Organon through its acquisition of Forendo Pharma in 2021. Following results from a Phase 2 clinical study with OG-6219, Organon plans to discontinue the clinical development of the drug candidate....

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, ISRAEL, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE IS UNLAWFUL OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH ACTION. REFER TO THE SECTION "IMPORTANT...

Episurf Medical (Nasdaq: EPIS B) today announces that the company is initiating re-structuring initiatives to significantly reduce its operating expenses while still positioning itself for further growth. The initiatives are expected to lead to annual cost savings of SEK 20 million. The company will significantly reduce operating expenses by reducing headcount, primarily impacting operations and sales in the European business. Episurf continues reorganising its sales organisation in Europe to handle sales through distributors, allowing a cost-effective business organisation that still...

STOCKHOLM, SE / ACCESS Newswire / July 2, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - At an extraordinary general meeting in AlzeCure Pharma AB on July 2, 2025, the shareholders decided to appro......

The information contained in this press release is not for publication, release or distribution, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, South Korea, Russia, Belarus or any other jurisdiction where such publication or distribution would be contrary to applicable laws or regulations. Please see “Important information” at the end of this press release.   The Board of Directors of OncoZenge AB (publ) (“OncoZenge” or the “Company”) has, based on renewed authorisation granted by the Annual...

Retransmission of the press release that was published, with the associated MAR label, on July 1st, 2025 at 16:45. Scandinavian ChemoTech AB's Animal Care division proudly announces record-breaking sales in the second quarter of 2025. With continued momentum from a strong start to the quarter, the team achieved sales totaling USD 390,000, representing nearly 60% of the total revenue generated during all of 2024 — in just one quarter. Including the first quarter, ChemoTech's Animal Care division has reached USD 630,000 in total sales during the first half of 2025. This is almost the same...

Company to Scale and Optimize Global Category-Led, Market Activation Growth Model Roberto Khoury, EVP & President Consumer Self-Care International (CSCI), Appointed to New Position of EVP & Chief Commercial Officer to Lead Global Market Activation Triona Schmelter, EVP & President......

Scandinavian ChemoTech AB's Animal Care division proudly announces record-breaking sales in the second quarter of 2025. With continued momentum from a strong start to the quarter, the team achieved sales totaling USD 390,000, representing nearly 60% of the total revenue generated during all of 2024 — in just one quarter. Including the first quarter, ChemoTech's Animal Care division has reached USD 630,000 in total sales during the first half of 2025. This is almost the same as the total sales for all of 2024, showing strong demand and good results from the company's Key Account strategy....

UPPSALA, SWEDEN / ACCESS Newswire / July 1, 2025 / Senzime AB (STO:SEZI)(OTCQX:SNZZF) today announced it has secured a contract to supply TetraGraph monitors and enter a scientific collaboration wi......

To support the cosmetic and petrochemical industries in key markets, Getinge is extending its range of Lancer Ultima Freestanding Washers with the new heavy-duty model Ultima 1600 LXP/HE-HD. [image] The Ultima1600LXP/HE heavy-duty model is designed to clean components used in the cosmetics industry, as well as different glassware used in petrochemical laboratories.   “Input from our local organizations indicates that there is an increased demand for heavy-duty washers in key markets, such as the United States and France, and the Ultima1600LXP/HE-HD has the capability and high-quality...